Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 12064420 Tie-2 activators targeting the Schlemm's canal

Patent 12064420 was granted and assigned to EyePoint Pharmaceuticals on August, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
0
Date Filed
January 6, 2022
0
Date of Patent
August 20, 2024
0
Patent Applicant
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
0
Patent Application Number
17569838
0
Patent Citations
‌
US Patent 7589212 Human protein tyrosine phosphatase inhibitors and methods of use
0
‌
US Patent 7622593 Human protein tyrosine phosphatase inhibitors and methods of use
0
‌
US Patent 7632862 Pharmaceutical compositions that modulate HPTPbeta activity
0
‌
US Patent 7740846 Inhibitors of angiopoietin-like 4 protein, combinations, and their use
0
‌
US Patent 7769575 Three dimensional coordinates of HPTPbeta
0
‌
US Patent 7795444 Human protein tyrosine phosphatase inhibitors and methods of use
0
‌
US Patent 7973142 Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
0
‌
US Patent 8106078 Human protein tyrosine phosphatase inhibitors and methods of use
0
‌
US Patent 8188125 Human protein tyrosine phosphatase inhibitors and methods of use
0
‌
US Patent 8258311 Human protein tyrosine phosphatase inhibitors and methods of use
0
•••
Patent Inventor Names
Kevin Peters
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12064420
0
Patent Primary Examiner
‌
Erich A Leeser
0
CPC Code
‌
A61K 31/426
0
‌
A61K 9/0048
0
‌
A61P 27/02
0

Find more entities like US Patent 12064420 Tie-2 activators targeting the Schlemm's canal

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo